Genmab ( (GMAB) ) just unveiled an announcement.
On April 1, 2025, Genmab A/S announced transactions involving shares and linked securities conducted by its managerial employees and their closely associated persons. The disclosure, in compliance with market abuse regulations, highlights the acquisition of shares due to the vesting of restricted stock units by a member of the Board of Directors. This announcement underscores Genmab’s commitment to transparency and regulatory compliance, potentially impacting stakeholder trust and the company’s market position.
More about Genmab
Genmab is an international biotechnology company based in Copenhagen, Denmark, with a focus on developing innovative and differentiated antibody therapeutics. Established in 1999, the company has a strong presence across North America, Europe, and Asia Pacific. Genmab’s proprietary pipeline includes bispecific T-cell engagers, antibody-drug conjugates, and next-generation immune checkpoint modulators, aiming to transform the lives of people with cancer and other serious diseases by 2030.
YTD Price Performance: -6.76%
Average Trading Volume: 1,490,161
Technical Sentiment Signal: Buy
Current Market Cap: $12.35B
See more data about GMAB stock on TipRanks’ Stock Analysis page.